Vanguard Capital Management
CLRB icon

Vanguard Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Vanguard Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$572K Sell
310,898
-16,469
-5% -$40.7K ﹤0.01% 3662
2026
Q2 		$910K Buy
327,367
+245,483
+300% +$687K ﹤0.01% 3612
2026
Q1 		$208K Buy
+81,884
New +$264K ﹤0.01% 3793

Other funds holding CLRB

Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
Bleichroeder LP
Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Sequoia Financial Advisors
Sequoia Financial Advisors Akron, Ohio $21.1B AUM 17.48% 1-Year Est. Return
Persistent Asset Partners
Persistent Asset Partners Hong Kong $362M AUM 191.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management's CLRB Position: Q3 2026 in Review

Vanguard Capital Management reduced its Cellectar Biosciences (CLRB) stake by 5% in Q3 2026, selling an estimated $40.7K and leaving 310,898 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #3662.

Vanguard Capital Management first reported a position in CLRB in Q1 2026 and has held it in 3 quarters since. The position peaked at $910K in Q2 2026. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2026.

  • Vanguard Capital Management held 310,898 shares of Cellectar Biosciences worth $572K as of Q3 2026.
  • Vanguard Capital Management sold 16,469 Cellectar Biosciences shares in Q3 2026, an estimated $40.7K.
  • Cellectar Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3662 holding.
  • Vanguard Capital Management first reported a position in Cellectar Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Cellectar Biosciences position peaked at $910K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.